Page 3 - Rna Interference News Today

Dublin, Dec. 01, 2022 (GLOBE NEWSWIRE) -- The "RNAi Technology Market, By Application, By Geography - Size, Share, Outlook, and Opportunity Analysis,...

Amgen posted positive Phase 2 data for olpasiran, further building the case for the drug's blockbuster potential in heart disease as it proceeds to a pivotal test. Arrowhead Pharmaceuticals, which originally developed olpasiran and licensed it to the big pharma company, is cashing in now by selling its royalty rights to the molecule.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced its second place ranking in Science Magazine’s 2022 Top Employer Survey .

Assistant Professor Omar F. Khan ( back row, second from left) and his lab team focus on diseases that are currently incurable and untreatable (photo by Safa Jinje)

Dublin, Sept. 28, 2022 (GLOBE NEWSWIRE) -- The "Transfection Technologies Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast...

The EC approval is based on positive 18-month results from the HELIOS-A Phase 3 study, where AMVUTTRA significantly improved the signs and symptoms of hATTR amyloidosis, with more than 50 percent of patients experiencing halting or reversal of their polyneuropathy manifestations.

Read user reviews, compare products and contact manufacturers of RNAi products, including assays, libraries and vectors on SelectScience.

In patients with PH1 and advanced kidney disease, including patients on hemodialysis, use of Lumasiran shows substantial reductions in plasma oxalate levels with acceptable safety.

Researchers at Saint Louis University's School of Medicine, in collaboration with Arrowhead Pharmaceuticals and Takeda Pharmaceuticals, report the first effective drug to treat a rare, genetic liver disease that formerly could only be treated with a liver transplant.

Ill be fine. i havent broken the law, _ ill be fine. i havent broken the law, i_ ill be fine. i havent broken the law, i havent done anything wrong, so why— law, i havent done anything wrong, so why should i be afraid, right? last _ so why should i be afraid, right? last year. — so why should i be afraid, right? last year, several editors were arrested under the national security law. he was released without charge. pro—beijing lawmakers essay the national security law was needed to return...